Azilsartan Medoxomil in Hypertensive pAtients With Stable Ischemic Heart Disease and DiabEtes MEllitus.

Inclusion Criteria: 1. Informed consent signed by the patient. 2. Men and women aged 18 years and older with a previously diagnosed hypertension and type 2 diabetes mellitus and stable ischemic heart disease. 3. Stable therapy of hypertension, T2DM and ischemic heart disease for at least 12 weeks before screening. 4. Not achievement of target values \* of blood pressure against the background of previously prescribed and steadily accepted antihypertensive therapy. \* not reaching the target figures of arterial pressure means mean systolic blood pressure more than 130 mm Hg and / or an average diastolic blood pressure more than 90 mmHg. 5. Investigator's decision on the advisability of correction of previously prescribed therapy with the replacement of ACE inhibitors or other ARBs with azilsartan medoxomil. Exclusion Criteria: 1. Contraindications to the azilsartan medoxomil in accordance with instruction for use, including information on the individual intolerance of the drug. 2. Any circumstances in the opinion of the investigator that interfere with the participation of the patient in the study. 3. The patient included in the study is an employee of the center or a relative of the investigator. 4. Participation in other clinical trials. Participation in register studies is allowed. 5. Any disease or condition that leads to a decrease in the patient's life expectancy.